inhaled human insulin + insulin detemir

Inhaled human insulin + insulin detemir is a combination of a rapid-acting inhaled human insulin formulation and a long-acting basal insulin analog (insulin detemir). Inhaled human insulin is designed for prandial (mealtime) glucose control and is delivered via pulmonary absorption, leading to a rapid onset of action and short duration. Insulin detemir, typically delivered by subcutaneous injection, serves as a long-acting basal insulin to maintain fasting glucose levels, with a duration of up to 24 hours due to its albumin-binding properties. This combination can be used as part of a basal-bolus insulin regimen, targeting both postprandial and basal glycemic control in diabetes mellitus, particularly type 1 and type 2 diabetes. Inhaled insulins (e.g., Exubera) have comparable efficacy to subcutaneous injection but feature differences in safety, antibody response, and pulmonary profile. Insulin detemir reduces glycemic variability and weight gain risks compared to other insulins.